Do RSV vaccines work as well in nursing homes? new study investigates
NCT ID NCT06077149
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how well licensed RSV vaccines (Pfizer's Abrysvo or GSK's Arexvy) trigger an immune response in adults over 60 living in long-term care facilities compared to those living independently in the community. Researchers measured antibody levels before and 30 days after vaccination in 152 participants. The goal is to see if these vaccines protect vulnerable nursing home residents as effectively as they protect community-dwelling older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSV vaccine (Pfizer's Abrysvo or GSK's Arexvy)
- What this could lead to
- If successful, this could show that RSV vaccines protect older adults in nursing homes as well as they protect those living independently.
- What could go wrong
- This is a small, completed Phase 4 study (152 participants) comparing immune responses, not preventing illness. Results may not apply to all older adults or predict real-world protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester Medical Center
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies